AZ ACQUISITION OF TAKEDA'S RESPIRATORY BUSINESS
ASTRAZENECA TO STRENGTHEN THERAPY AREA FRANCHISE THROUGH ACQUISITION OF TAKEDA'S RESPIRATORY BUSINESS Acquisition to include non-US rights to roflumilast and will be accretive to 2016 earnings, contributing to AstraZeneca's return to growth strategy AstraZeneca today announced that it has entered into a definitive agreement to acquire the core respiratory business of Takeda Pharmaceutical Company Limited ("Takeda"). The deal will include the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for